Connect with us

Business

FDA Adviser Quits Over ‘Probably The Worst’ Approval Decision Of Alzheimer’s Drug – HuffPost

The controversial drug, called Aduhelm, costs $56,000 a year and some patients could face copayments of $11,500 annually.

Published

on

Article feature image
ADVERTISEMENT

WASHINGTON (AP) A new $56,000-a-year Alzheimers drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.
The drug,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Amazon details new warehouse robots, ‘Ernie’ and ‘Bert’ – CNBC
Article feature image
Fed decision, retail sales: What to know this week – Yahoo Finance
Article feature image
Eager to travel, Americans book Sun Belt beach, city stays as pandemic fades – CNBC